Dynamic Plasma Exosome-Derived Multi-Analyte Panel Combining YKL-40, sTREM2, and Neurogranin

This hypothesis proposes that plasma-derived exosomes carrying YKL-40, sTREM2, and neurogranin provide a superior biomarker platform compared to CSF analysis by capturing real-time bidirectional brain-periphery communication. Exosomes released from activated microglia (sTREM2), reactive astrocytes (YKL-40), and compromised neurons (neurogranin) cross the blood-brain barrier and maintain molecular integrity in circulation for 6-48 hours, creating a dynamic temporal window for neurodegeneration assessment. The exosomal compartmentalization protects these biomarkers from plasma proteases while concentrating them 10-50 fold relative to free circulating levels. Crucially, exosome surface markers (CD81, GFAP, IBA1) enable cell-type-specific isolation, allowing separate quantification of microglial-derived sTREM2 versus astrocyte-derived sTREM2, which may have opposing prognostic implications. The temporal kinetics of exosomal release differ from CSF accumulation: exosomal biomarkers peak within hours of cellular stress, while CSF levels reflect sustained tissue damage over days to weeks. This creates opportunity for earlier intervention windows and real-time monitoring of therapeutic responses. The weighted algorithm incorporates exosome concentration, biomarker cargo density, and surface marker profiles to generate a composite neuroinflammatory-synaptic stress index. Validation requires demonstrating that plasma exosomal levels correlate with brain pathology independently of CSF levels, and that temporal changes predict clinical progression with superior sensitivity to current CSF-based approaches.